Lexicon Pharmaceuticals to Participate in December Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in two major investor conferences this December. CEO Mike Exton will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 8:00 am ET, and the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024, at 12:30 pm ET.
Live webcasts of both presentations will be accessible through the Events section of Lexicon's website, with recordings available for two weeks after the original broadcasts.
Details
News Market Reaction – LXRX
The recorded move for LXRX in the trading session of this news was +0.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer and director, will present at two upcoming investor conferences in December.
- Piper Sandler 36th Annual Healthcare Conference: Presentation Tuesday, December 3, 2024 at 8:00 am ET
- 7th Annual Evercore HealthCONx Conference: Presentation Thursday, December 5, 2024 at 12:30 pm ET
Simultaneous webcasts will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events, and a recording of the webcasts will be available for two weeks following the original on-demand date.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com.
Investors and Media
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.